Effects of lupeol and flutamide on experimentally-induced polycystic ovary syndrome in mice

Document Type : Original Article

Authors

1 Department of Basic Sciences, School of Veterinary Medicine, Ardakan University, Ardakan, Iran

2 Biology and Animal Reproduction Science Research Institute, Ardakan University, Ardakan, Iran

3 Department of Comparative Histology and Embryology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran

4 Department of Anatomy, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran

5 Department of Pharmacology and Toxicology, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran

10.22038/ijbms.2024.77602.16783

Abstract

Objective(s): Polycystic ovary syndrome (PCOS) is one of the main causes of infertility in women. This study was conducted to uncover the effects of lupeol as an anti-androgenic triterpene on experimentally-induced PCOS in mice. 
Materials and Methods: Eighty immature female mice were divided into 4 groups: Control (C), PCOS (P), Lupeol (L), and Flutamide (F). PCOS was induced in test groups by injection of Dehydroepiandrosterone (60 mg/kg/day, IP) for twenty days. Following the PCOS induction, the two groups of L and F were treated with lupeol (40 mg/kg/day) and/or flutamide (10 mg/kg/day) respectively and the two groups of C and P received sesame oil (0.1 ml/mouse/day) for 15 days. After the treatment period, ten animals in each group were selected for collecting blood and ovary samples. In vitro  fertilization assessment was carried out on 10 remaining mice in each group. The hormonal assays and oxidative stress biomarker determination were performed on serum and tissue samples. Moreover, histopathological analyses were conducted on the ovaries.
Results: PCOS-elevated concentration of LH and Testosterone was significantly (P<0.05) lowered in lupeol and flutamide-received animals. Lupeol and flutamide both reduced PCOS-induced fibrosis and the number of atretic follicles. Both compounds declined the PCOS-increased lipid peroxidation and protein oxidation in serum and the ovaries. Lupeol increased the PCOS-reduced fertility rate and decreased the number of arrested embryos by 12%. 
Conclusion: These findings indicate that lupeol could be a novel compound in the treatment of PCOS as it reduced PCOS-induced structural and also functional disorders.

Keywords

Main Subjects

References

1. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010; 8: 1-10.
2. Hull M. Epidemiology of infertility and polycystic ovarian disease: Endocrinological and demographic studies. Gynecol Endocrinol 1987; 1: 235-245.
3. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007; 370: 685-697.
4. Oakley O, Lin P-C, Bridges P, Ko C. Animal models for the study of polycystic ovarian syndrome. Endocrinol Metab 2011; 26: 193-202.
5. Lea RW, Clark JA, Tsutsui K. Changes in central steroid receptor expression, steroid synthesis, and dopaminergic activity related to the reproductive cycle of the ring dove. Microsc Res Tech 2001; 55: 12-26.
6. Ozawa H. Steroid hormones, their receptors and neuroendocrine system. J Nippon Med Sch 2005; 72: 316-325.
7. Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, Marshall JC. Polycystic ovary syndrome: Evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 1998; 83: 582-590.
8. Firmansyah A, Chalid MT, Farid RB, Nusratuddin N. The correlation between insulin-like growth factor binding protein 1 (IGFBP-1) and homeostasis model assessment of insulin resistance (HOMA-IR) in polycystic ovarian syndrome with insulin resistance. Int J Reprod Biomed 2018; 16: 679–682.
9. Nagamani M, Stuart CA. Specific binding sites for insulin-like growth factor I in the ovarian stroma of women with polycystic ovarian disease and stromal hyperthecosis. Am J Obstet Gynecol 1990; 163: 1992-1997.
10. Homburg R, Pariente C, Lunenfeld B, Jacobs H. The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome. Hum Reprod 1992; 7: 1379-1383.
11. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-Month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139-146.
12. Simard J, Luthy I, Guay J, Belanger A, Labrie F. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 1986; 44: 261-270.
13. Marcondes JA, Minnani SL, Luthold WW, Wajchenberg BL, Samojlik E, Kirschner MA. Treatment of hirsutism in women with flutamide. Fertil Steril 1992; 57: 543-547.
14. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85: 89-94.
15. Ibáñez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update 2006; 12: 243-252.
16. Ibáñez L, Valls C, Ferrer A, Ong K, Dunger DB, de Zegher F. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab 2002; 87: 2870-2874.
17. De Leo V, Lanzetta D, D’Antona D, la Marca A, Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 99-102.
18. Wirth M, Fröhner M. A review of studies of hormonal adjuvant therapy in prostate cancer. Eur Urol. 1999; 36: 14-19.
19. Gomez J-L, Dupont A, Cusan L, Tremblay M, Suburu R, Lemay M, et al. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 1992; 92: 465-470.
20. Wallace C, Lalor E, Chik CL. Hepatotoxicity complicating flutamide treatment of hirsutism. Ann Intern Med 1993; 119: 1150.
21. Ovesna Z, Vachalkova A, Horvathova K, Tothova D. Pentacyclic triterpenoic acids: New chemoprotective compounds Minireview. Neoplasma 2004; 51: 327-333.
22. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007; 7: 357-369.
23. Bradford PG, Awad AB. Phytosterols as anticancer compounds. Mol Nutr Food Res 2007; 51: 161-170.
24. Saleem M, Murtaza I, Witkowsky O, Kohl AM, Maddodi N. Lupeol triterpene, a novel diet-based microtubule targeting agent: Disrupts survivin/cFLIP activation in prostate cancer cells. Biochem Biophys Res Commun 2009; 388: 576-582. 
25. Saleem M. Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett 2009; 285: 109-115.
26. Fernández MA, de las Heras B, Garcia MD, Sáenz MT, Villar A. New insights into the mechanism of action of the anti‐inflammatory triterpene lupeol. J Pharm Pharmacol 2001; 53: 1533-1539.
27. Murtaza I, Saleem M, Adhami VM, Hafeez BB, Mukhtar H. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res 2009; 69: 1156-1165.
28. Lee TK, Poon RT, Wo JY, Ma S, Guan X-Y, Myers JN, et al. Lupeol suppresses cisplatin-induced nuclear factor-κB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res 2007; 67: 8800-8809.
29. Preetha S, Kanniappan M, Selvakumar E, Nagaraj M, Varalakshmi P. Lupeol ameliorates aflatoxin B1-induced peroxidative hepatic damage in rats. Comp Biochem Physiol C Toxicol Pharmacol. 2006; 143: 333-339.
30. Geetha T, Varalakshmi P, Latha RM. Effect of triterpenes from Crataeva nurvala stem bark on lipid peroxidation in adjuvant induced arthritis in rats. Pharmacol Res 1998; 37: 191-195.
31. Malekinejad H, Zeynali-Moghaddam S, Rezaei-Golmisheh A, Alenabi A, Malekinejad F, Alizadeh A, et al. Lupeol attenuated the NAFLD and PCOS-induced metabolic, oxidative, hormonal, histopathological, and molecular injuries in mice. Res Pharm Sci 2023; 18: 551-565.
32. Sudhahar V, Kumar SA, Varalakshmi P, Sujatha V. Protective effect of lupeol and lupeol linoleate in hypercholesterolemia associated renal damage. Mol Cell Biochem 2008; 317: 11-20.
33. Ahmed Y, Sohrab MH, Al-Reza SM, Tareq FS, Hasan CM, Sattar M. Antimicrobial and cytotoxic constituents from leaves of Sapium baccatum. Food Chem Toxicol 2010; 48: 549-552.
34. Saleem M, Kweon M-H, Yun J-M, Adhami VM, Khan N, Syed DN, et al. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model. Cancer Res 2005; 65: 11203-11213.
35. Siddique HR, Mishra SK, Karnes RJ, Saleem M. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin Cancer Res 2011; 17: 5379-5391.
36. Wang X, Gu L, Zhang Y, Xiong C, Peng Y, Ding X. Effects of dehydroepiandrosterone alone or in combination with a high-fat diet and antibiotic cocktail on the heterogeneous phenotypes of PCOS mouse models by regulating gut microbiota. Front Endocrinol 2022; 13: 1030151.
37. Tilly JL. Ovarian follicle counts–not as simple as 1, 2, 3. Reprod Biol Endocrinol 2003; 1: 1-4.
38. Townson DH, Combelles CM. Ovarian follicular atresia: Intech Open Access; 2012.p.43-76.
39. Zhang X, Zhang C, Shen S, jie Xia Y, Yi L, Gao Q, et al. Dehydroepiandrosterone induces ovarian and uterine hyperfibrosis in female rats. Hum Reprod 2013; 28: 3074-3085.
40. Kondou H, Mushiake S, Etani Y, Miyoshi Y, Michigami T, Ozono K. A blocking peptide for transforming growth factor-β1 activation prevents hepatic fibrosis in vivo. J Hepatol 2003; 39:742-748.
41. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, et al. Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106: 130-135.
42. Benzie IF, Strain J. Ferric reducing/antioxidant power assay: Direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Enzymol 1999; 299: 15-27.
43. Niehaus W, Samuelsson B. Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem 1968; 6: 126-130.
44. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
45. Luo C, Zuñiga J, Edison E, Palla S, Dong W, Parker-Thornburg J. Superovulation strategies for 6 commonly used mouse strains. J Am Assoc Lab Anim Sci 2011; 50: 471-478.
46. Manas GE, Hasanzadeh S, Najafi G, Parivar K, Yaghmaei P. The effects of pyridaben pesticide on the DNA integrity of sperms and early in vitro embryonic development in mice. Iran J Reprod Med 2013; 11: 605-610.
47. Solorzano CMB, Beller JP, Abshire MY, Collins JS, McCartney CR, Marshall JC. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids 2012; 77: 332-337.
48. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, et al. Polycystic ovarian syndrome: Evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000; 85: 4047-4052.
49. Group REASPCW. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reprod 2004; 19:41-47.
50. Wang Q, Kim JY, Xue K, Liu J-y, Leader A, Tsang BK. Chemerin, a novel regulator of follicular steroidogenesis and its potential involvement in polycystic ovarian syndrome. Endocrinology 2012; 153: 5600-5611.
51. Himelstein-Braw R, Byskov AG, Peters H, Faber M. Follicular atresia in the infant human ovary. Reproduction 1976; 46: 55-59.
52. Bulut G, Kurdoglu Z, Dönmez YB, Kurdoglu M, Erten R. Effects of jnk inhibitor on inflammation and fibrosis in the ovary tissue of a rat model of polycystic ovary syndrome. Int J Clin Exp Pathol. 2015; 8: 8774.
53. Zangeneh FZ, Naghizadeh MM, Masoumi M. Polycystic ovary syndrome and circulating inflammatory markers. Int J Reprod Biomed 2017; 15: 375.
54. González F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 336-340.
55. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012; 33: 981-1030.
56. Mohammadi M. Oxidative stress and polycystic ovary syndrome: a brief review. Int J Prev Med 2019; 10: 86-92.
57. Attard G, Richards J, de Bono JS. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011; 17: 1649-1657.
58. Sziksz E, Pap D, Lippai R, Béres NJ, Fekete A, Szabó AJ, et al. Fibrosis related inflammatory mediators: role of the IL-10 cytokine family. Mediators Inflamm 2015; 2015:764641
59. Lucetti DL, Lucetti EC, Bandeira MAM, Veras HN, Silva AH, Leal LKA, et al. Anti-inflammatory effects and possible mechanism of action of lupeol acetate isolated from Himatanthus drasticus (Mart.) Plumel. J Inflamm 2010; 7: 1-11.
60. Sudhahar V, Kumar SA, Varalakshmi P, Sundarapandiyan R. Mitigating role of lupeol and lupeol linoleate on hepatic lipemic-oxidative injury and lipoprotein peroxidation in experimental hypercholesterolemia. Mol Cell Biochem 2007; 295: 189-198.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 08 May 2024

Files

Share

How to cite

Statistics